Komori
Chordia Therapeutics (190A) · TargetFirst stated

Secure stable revenue streams through regulatory approvals or licensing agreements

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Product sales and stable monetization through regulatory approval and licensingA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「The Company's most important medium- to long-term challenge is to steadily advance the R&D of new anticancer drugs, obtain regulatory approval or enter into license agreements, and secure stable revenue from product sales by the Company or partner companies.」

    Securing stable revenue through regulatory approval, license agreements and sales by the Company or its partners was identified as the most important medium- to long-term challenge.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Secure stable revenue streams through regulatory approvals or licensing agreements | Chordia Therapeutics Inc. (190A) | Komori